Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 64-year-old man is evaluated in the clinic for a routine follow-up. Six months ago, he was diagnosed with highly symptomatic paroxysmal atrial fibrillation and was started on amiodarone for rhythm control. His other medical conditions include hypertension and type 2 diabetes mellitus. His current medications are amiodarone, lisinopril, metformin, and apixaban. He reports feeling well and denies palpitations, shortness of breath, cough, fatigue, heat intolerance, or visual changes. His pulse is 68/min, and blood pressure is 122/78 mmHg. Physical examination, including pulmonary auscultation and neurologic assessment, is unremarkable. An electrocardiogram performed today shows normal sinus rhythm with a heart rate of 66/min and a QTc interval of 440 msec. Baseline chest radiograph, pulmonary function tests, and laboratory studies were normal prior to amiodarone initiation. Which of the following is the most appropriate next step in the monitoring of this patient's pharmacotherapy?

  1. Obtain serum thyroid-stimulating hormone and hepatic aminotransferase levelsAnswer
  2. B
    Measure prothrombin time and international normalized ratio
  3. C
    Perform pulmonary function tests with diffusion capacity for carbon monoxide
  4. D
    Order a high-resolution computed tomography scan of the chest
  5. E
    Check a serum amiodarone trough concentration

Answer

Obtain serum thyroid-stimulating hormone and hepatic aminotransferase levels
Amiodarone is an iodine-rich class III antiarrhythmic agent associated with significant long-term, multi-organ toxicity, primarily affecting the thyroid, liver, and lungs. Because of its large volume of distribution, long half-life, and tissue accumulation, structured longitudinal surveillance is mandatory. Guidelines recommend obtaining a baseline thyroid-stimulating hormone (TSH), free T4, and hepatic panel, followed by repeat testing every 6 months. Therefore, checking TSH and hepatic aminotransferase levels is the correct monitoring step for this asymptomatic patient at his 6-month follow-up visit. Additionally, an electrocardiogram should be performed every 3 to 6 months to monitor for QTc prolongation and bradycardia, which was appropriately completed during this visit.

Step-by-Step Solution

1
Identify the primary intervention requiring monitoring.
The patient is on chronic amiodarone therapy for atrial fibrillation rhythm control.
Amiodarone is a high-risk medication with a known profile of substantial long-term toxicities, requiring a structured surveillance protocol.
2
Determine the time elapsed since initiation and current symptoms.
It has been 6 months since initiation, and the patient is completely asymptomatic.
The timing dictates which surveillance tests are due. At 6 months, specific end-organ laboratory monitoring is universally recommended regardless of symptoms.
3
Apply guideline-based monitoring recommendations for amiodarone at the 6-month mark.
Guidelines recommend checking thyroid-stimulating hormone (TSH), free T4, and liver aminotransferases every 6 months.
Amiodarone can cause hypo- or hyperthyroidism and hepatotoxicity. Routine testing detects subclinical organ dysfunction before severe toxicity develops.

Key Concept

Patients receiving chronic amiodarone therapy require routine monitoring of hepatic aminotransferases and thyroid function tests (TSH) every 6 months to detect asymptomatic end-organ toxicity.
Estimated Time:1m 0s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic